Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma.

IK-930 is a TEAD inhibitor designed to target the Hippo signaling pathway.

Earlier this year, IK-930 was granted the FDA orphan drug designation for the treatment of patients having malignant pleural mesothelioma.

Sergio Santillana — Chief Medical Officer at Ikena Oncology said: “We are delighted to announce that IK-930 has been granted Fast Track designation, demonstrating the potential of IK-930 to address the unmet medical need of people with unresectable NF2-deficient MPM.

“This milestone, combined with the Orphan Drug designation in mesothelioma, further validates our targeted oncology approach to address significant unmet medical needs for difficult-to-treat cancers and supports our goal to advance the development of IK-930 for the patients who potentially could benefit most.”

Presently, IK-930 is being evaluated as a monotherapy in a phase 1 clinical trial in patients having advanced solid tumors irrespective of gene alterations in the Hippo pathway.

  Advanced solid tumors, cancer, IK-930, malignant pleural mesothelioma, mesothelioma, Oncology, pleural mesothelioma, Sergio Santillana, Solid tumors, US FDA, US Food and Drug Administration